🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are escalating around the world, with estimates suggesting in excess of 82 million infections annually. Notably increased rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the reality of rising global incidence, the spread of superbugs and the highly restricted therapeutic options presently on offer.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts hope that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the drug firm Innoviva to develop it.

“This authorization represents a significant shift in the management of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Data and Global Access

According to results released by a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The trial involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the ability to make available and distribute the drug in numerous developing nations.

Medical professionals treating patients have shared optimism. The availability of a easy-to-administer therapy such as this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as vital to alleviate the strain of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.